Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 248

1.

Capturing Exacerbations of Chronic Obstructive Pulmonary Disease with EXACT: A Sub-Analysis of FLAME.

Frent SM, Chapman KR, Larbig M, Mackay A, Fogel R, Gutzwiller FS, Shen S, Patalano F, Banerji D, Kostikas K, Wedzicha JA.

Am J Respir Crit Care Med. 2018 Jul 18. doi: 10.1164/rccm.201801-0038OC. [Epub ahead of print]

PMID:
30019939
2.

Long-term Triple Therapy De-escalation to Indacaterol/Glycopyrronium in COPD Patients (SUNSET): a Randomized, Double-Blind, Triple-Dummy Clinical Trial.

Chapman KR, Hurst JR, Frent SM, Larbig M, Fogel R, Guerin T, Banerji D, Patalano F, Goyal P, Pfister P, Kostikas K, Wedzicha JA.

Am J Respir Crit Care Med. 2018 May 20. doi: 10.1164/rccm.201803-0405OC. [Epub ahead of print]

3.

Lower Aerobic Endurance Linked to History of Depression in Multiple Sclerosis: Preliminary Observations.

Chapman KR, Anderson JR, Calvo D, Pollock BS, Petersen J, Gerhart H, Ridgel A, Spitznagel MB.

J Neurosci Nurs. 2018 Jun;50(3):167-170. doi: 10.1097/JNN.0000000000000360.

PMID:
29727394
4.

Exacerbation heterogeneity in COPD: subgroup analyses from the FLAME study.

Vogelmeier CF, Chapman KR, Miravitlles M, Roche N, Vestbo J, Thach C, Banerji D, Fogel R, Patalano F, Olsson P, Kostikas K, Wedzicha JA.

Int J Chron Obstruct Pulmon Dis. 2018 Apr 10;13:1125-1134. doi: 10.2147/COPD.S160011. eCollection 2018.

5.

Long-Term Evaluation of the Effects of Aclidinium Bromide on Major Adverse Cardiovascular Events and COPD Exacerbations in Patients with Moderate to Very Severe COPD: Rationale and Design of the ASCENT COPD Study.

Wise RA, Chapman KR, Scirica BM, Schoenfeld DA, Bhatt DL, Daoud SZ, Seoane B, Reisner C, Garcia Gil E.

Chronic Obstr Pulm Dis. 2018 Jan 24;5(1):5-15. doi: 10.15326/jcopdf.5.1.2017.0149.

6.

Alpha 1 antitrypsin to treat lung disease in alpha 1 antitrypsin deficiency: recent developments and clinical implications.

Chapman KR, Chorostowska-Wynimko J, Koczulla AR, Ferrarotti I, McElvaney NG.

Int J Chron Obstruct Pulmon Dis. 2018 Jan 31;13:419-432. doi: 10.2147/COPD.S149429. eCollection 2018. Review.

7.

Health Services Burden of Undiagnosed and Overdiagnosed COPD.

Gershon AS, Thiruchelvam D, Chapman KR, Aaron SD, Stanbrook MB, Bourbeau J, Tan W, To T; Canadian Respiratory Research Network.

Chest. 2018 Jun;153(6):1336-1346. doi: 10.1016/j.chest.2018.01.038. Epub 2018 Feb 6.

PMID:
29425675
8.

Asthma biomarkers in the age of biologics.

Kim H, Ellis AK, Fischer D, Noseworthy M, Olivenstein R, Chapman KR, Lee J.

Allergy Asthma Clin Immunol. 2017 Nov 17;13:48. doi: 10.1186/s13223-017-0219-4. eCollection 2017. Review.

9.

Physician perspectives on the burden and management of asthma in six countries: The Global Asthma Physician Survey (GAPS).

Chapman KR, Hinds D, Piazza P, Raherison C, Gibbs M, Greulich T, Gaalswyk K, Lin J, Adachi M, Davis KJ.

BMC Pulm Med. 2017 Nov 23;17(1):153. doi: 10.1186/s12890-017-0492-5.

10.

Self-Management and Clinical Decision Support for Patients With Complex Chronic Conditions Through the Use of Smartphone-Based Telemonitoring: Randomized Controlled Trial Protocol.

Seto E, Ware P, Logan AG, Cafazzo JA, Chapman KR, Segal P, Ross HJ.

JMIR Res Protoc. 2017 Nov 21;6(11):e229. doi: 10.2196/resprot.8367.

11.

Reply to Cooper et al.: The Significance of Eosinophilic Inflammation in Chronic Obstructive Pulmonary Disease.

Roche N, Chapman KR, Vogelmeier CF, Herth FJF, Thach C, Fogel R, Olsson P, Patalano F, Banerji D, Wedzicha JA.

Am J Respir Crit Care Med. 2018 Apr 1;197(7):968-969. doi: 10.1164/rccm.201710-2027LE. No abstract available.

PMID:
29140725
12.

Clinical Utility of Select Neuropsychological Assessment Battery Tests in Predicting Functional Abilities in Dementia.

Ashendorf L, Alosco ML, Bing-Canar H, Chapman KR, Martin B, Chaisson CE, Dixon D, Steinberg EG, Tripodis Y, Kowall NW, Stern RA.

Arch Clin Neuropsychol. 2017 Nov 8:1-11. doi: 10.1093/arclin/acx100. [Epub ahead of print]

PMID:
29126099
13.

Dual Bronchodilation Response by Exacerbation History and Eosinophilia in the FLAME Study.

Papi A, Kostikas K, Wedzicha JA, Vogelmeier CF, Roche N, Shen S, Banerji D, Fogel R, Patalano F, Chapman KR.

Am J Respir Crit Care Med. 2018 May 1;197(9):1223-1226. doi: 10.1164/rccm.201709-1822LE. No abstract available.

PMID:
29099609
14.

Work productivity loss in mild to moderate COPD: lessons learned from the CanCOLD study.

de Sousa Sena R, Ahmed S, Tan WC, Li PZ, Labonté L, Aaron SD, Benedetti A, Chapman KR, Walker B, Fitzgerald JM, Hernandez P, Maltais F, Marciniuk DD, O'Donnell DE, Sin DD, Bourbeau J; CanCOLD Collaborative Research Group and The Canadian Respiratory Research Network.

Eur Respir J. 2017 Sep 12;50(3). pii: 1701154. doi: 10.1183/13993003.01154-2017. Print 2017 Sep. No abstract available.

PMID:
28899939
15.

The Effect of Alpha-1 Proteinase Inhibitor on Biomarkers of Elastin Degradation in Alpha-1 Antitrypsin Deficiency: An Analysis of the RAPID/RAPID Extension Trials.

Ma S, Lin YY, Cantor JO, Chapman KR, Sandhaus RA, Fries M, Edelman JM, McElvaney G, Turino GM.

Chronic Obstr Pulm Dis. 2016 Nov 18;4(1):34-44. doi: 10.15326/jcopdf.4.1.2016.0156.

16.

Quantitative disease progression model of α-1 proteinase inhibitor therapy on computed tomography lung density in patients with α-1 antitrypsin deficiency.

Tortorici MA, Rogers JA, Vit O, Bexon M, Sandhaus RA, Burdon J, Chorostowska-Wynimko J, Thompson P, Stocks J, McElvaney NG, Chapman KR, Edelman JM.

Br J Clin Pharmacol. 2017 Nov;83(11):2386-2397. doi: 10.1111/bcp.13358. Epub 2017 Aug 11.

17.

Reply: What Should Be the Cutoff Value of Blood Eosinophilia as a Predictor of Inhaled Corticosteroid Responsiveness in Patients with Chronic Obstructive Pulmonary Disease?

Roche N, Chapman KR, Vogelmeier CF, Herth FJF, Thach C, Fogel R, Olsson P, Patalano F, Banerji D, Wedzicha JA.

Am J Respir Crit Care Med. 2017 Nov 1;196(9):1230-1231. doi: 10.1164/rccm.201706-1105LE. No abstract available.

PMID:
28650724
18.

Blood Eosinophils and Response to Maintenance Chronic Obstructive Pulmonary Disease Treatment. Data from the FLAME Trial.

Roche N, Chapman KR, Vogelmeier CF, Herth FJF, Thach C, Fogel R, Olsson P, Patalano F, Banerji D, Wedzicha JA.

Am J Respir Crit Care Med. 2017 May 1;195(9):1189-1197. doi: 10.1164/rccm.201701-0193OC.

19.

Long-term efficacy and safety of α1 proteinase inhibitor treatment for emphysema caused by severe α1 antitrypsin deficiency: an open-label extension trial (RAPID-OLE).

McElvaney NG, Burdon J, Holmes M, Glanville A, Wark PA, Thompson PJ, Hernandez P, Chlumsky J, Teschler H, Ficker JH, Seersholm N, Altraja A, Mäkitaro R, Chorostowska-Wynimko J, Sanak M, Stoicescu PI, Piitulainen E, Vit O, Wencker M, Tortorici MA, Fries M, Edelman JM, Chapman KR; RAPID Extension Trial Group.

Lancet Respir Med. 2017 Jan;5(1):51-60. doi: 10.1016/S2213-2600(16)30430-1. Epub 2016 Dec 2. Erratum in: Lancet Respir Med. 2017 Feb;5(2):e13.

PMID:
27916480
20.

Findings on Thoracic Computed Tomography Scans and Respiratory Outcomes in Persons with and without Chronic Obstructive Pulmonary Disease: A Population-Based Cohort Study.

Tan WC, Hague CJ, Leipsic J, Bourbeau J, Zheng L, Li PZ, Sin DD, Coxson HO, Kirby M, Hogg JC, Raju R, Road J, O'Donnell DE, Maltais F, Hernandez P, Cowie R, Chapman KR, Marciniuk DD, FitzGerald JM, Aaron SD; Canadian Respiratory Research Network and the CanCOLD Collaborative Research group.

PLoS One. 2016 Nov 18;11(11):e0166745. doi: 10.1371/journal.pone.0166745. eCollection 2016.

21.

Improving the Management of COPD in Women.

Jenkins CR, Chapman KR, Donohue JF, Roche N, Tsiligianni I, Han MK.

Chest. 2017 Mar;151(3):686-696. doi: 10.1016/j.chest.2016.10.031. Epub 2016 Nov 2. Review.

22.

Practice Effects on Story Memory and List Learning Tests in the Neuropsychological Assessment of Older Adults.

Gavett BE, Gurnani AS, Saurman JL, Chapman KR, Steinberg EG, Martin B, Chaisson CE, Mez J, Tripodis Y, Stern RA.

PLoS One. 2016 Oct 6;11(10):e0164492. doi: 10.1371/journal.pone.0164492. eCollection 2016.

23.

The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorized by symptom status: a pooled analysis.

Miravitlles M, Chapman KR, Chuecos F, Ribera A, Gil EG.

Int J Chron Obstruct Pulmon Dis. 2016 Aug 29;11:2041-53. doi: 10.2147/COPD.S114566. eCollection 2016.

24.

Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials.

Hanania NA, Korenblat P, Chapman KR, Bateman ED, Kopecky P, Paggiaro P, Yokoyama A, Olsson J, Gray S, Holweg CT, Eisner M, Asare C, Fischer SK, Peng K, Putnam WS, Matthews JG.

Lancet Respir Med. 2016 Oct;4(10):781-796. doi: 10.1016/S2213-2600(16)30265-X. Epub 2016 Sep 5.

PMID:
27616196
25.

The COPD Assessment Test: Can It Discriminate Across COPD Subpopulations?

Gupta N, Pinto L, Benedetti A, Li PZ, Tan WC, Aaron SD, Chapman KR, FitzGerald JM, Hernandez P, Marciniuk DD, Maltais F, O'Donnell DE, Sin D, Walker BL, Bourbeau J; Canadian Respiratory Research Network and the CanCOLD Collaborative Research Group.

Chest. 2016 Nov;150(5):1069-1079. doi: 10.1016/j.chest.2016.06.016. Epub 2016 Jun 27.

PMID:
27364603
26.

Factors associated with undiagnosed and overdiagnosed COPD.

Gershon AS, Hwee J, Chapman KR, Aaron SD, O'Donnell DE, Stanbrook MB, Bourbeau J, Tan W, Su J, Victor JC, To T.

Eur Respir J. 2016 Aug;48(2):561-4. doi: 10.1183/13993003.00458-2016. Epub 2016 Jun 23. No abstract available.

27.

Screening Utility of the King-Devick Test in Mild Cognitive Impairment and Alzheimer Disease Dementia.

Galetta KM, Chapman KR, Essis MD, Alosco ML, Gillard D, Steinberg E, Dixon D, Martin B, Chaisson CE, Kowall NW, Tripodis Y, Balcer LJ, Stern RA.

Alzheimer Dis Assoc Disord. 2017 Apr-Jun;31(2):152-158. doi: 10.1097/WAD.0000000000000157.

28.

Assessing biomarkers in a real-world severe asthma study (ARIETTA).

Buhl R, Korn S, Menzies-Gow A, Aubier M, Chapman KR, Canonica GW, Picado C, Martin N, Escobar RA, Korom S, Hanania NA.

Respir Med. 2016 Jun;115:7-12. doi: 10.1016/j.rmed.2016.04.001. Epub 2016 Apr 14.

29.

Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD.

Wedzicha JA, Banerji D, Chapman KR, Vestbo J, Roche N, Ayers RT, Thach C, Fogel R, Patalano F, Vogelmeier CF; FLAME Investigators.

N Engl J Med. 2016 Jun 9;374(23):2222-34. doi: 10.1056/NEJMoa1516385. Epub 2016 May 15.

30.

A Randomized Controlled Trial to Determine the Effect of Inhaled Corticosteroid on Intraocular Pressure in Open-Angle Glaucoma and Ocular Hypertension: The ICOUGH Study.

Moss EB, Buys YM, Low SA, Yuen D, Jin YP, Chapman KR, Trope GE.

J Glaucoma. 2017 Feb;26(2):182-186. doi: 10.1097/IJG.0000000000000429.

PMID:
27096722
31.

The relationship between omega-3 and smoking habit: a cross-sectional study.

Scaglia N, Chatkin J, Chapman KR, Ferreira I, Wagner M, Selby P, Allard J, Zamel N.

Lipids Health Dis. 2016 Mar 22;15:61. doi: 10.1186/s12944-016-0220-9.

32.

Mini Mental State Examination and Logical Memory scores for entry into Alzheimer's disease trials.

Chapman KR, Bing-Canar H, Alosco ML, Steinberg EG, Martin B, Chaisson C, Kowall N, Tripodis Y, Stern RA.

Alzheimers Res Ther. 2016 Feb 22;8:9. doi: 10.1186/s13195-016-0176-z.

33.

Current thinking and new paradigm for COPD.

Welte T, Chapman KR, Magnussen H, Miravitlles M.

Respir Med. 2016 Mar;112:126-7. doi: 10.1016/j.rmed.2015.10.014. Epub 2016 Jan 13.

34.

Undiagnosed Chronic Obstructive Pulmonary Disease Contributes to the Burden of Health Care Use. Data from the CanCOLD Study.

Labonté LE, Tan WC, Li PZ, Mancino P, Aaron SD, Benedetti A, Chapman KR, Cowie R, FitzGerald JM, Hernandez P, Maltais F, Marciniuk DD, O'Donnell D, Sin D, Bourbeau J; Canadian Respiratory Research Network; CanCOLD Collaborative Research Group.

Am J Respir Crit Care Med. 2016 Aug 1;194(3):285-98. doi: 10.1164/rccm.201509-1795OC.

PMID:
26836958
35.

Overall and Cardiovascular Safety of Aclidinium Bromide in Patients With COPD: A Pooled Analysis of Six Phase III, Placebo-Controlled, Randomized Studies.

Chapman KR, Beck E, Alcaide D, Garcia Gil E.

Chronic Obstr Pulm Dis. 2015 Dec 22;3(1):435-445. doi: 10.15326/jcopdf.3.1.2015.0148.

36.

Safety of inhaled glycopyrronium in patients with COPD: a comprehensive analysis of clinical studies and post-marketing data.

D'Urzo AD, Kerwin EM, Chapman KR, Decramer M, DiGiovanni R, D'Andrea P, Hu H, Goyal P, Altman P.

Int J Chron Obstruct Pulmon Dis. 2015 Aug 11;10:1599-612. doi: 10.2147/COPD.S81266. eCollection 2015.

37.
38.

Characteristics of COPD in never-smokers and ever-smokers in the general population: results from the CanCOLD study.

Tan WC, Sin DD, Bourbeau J, Hernandez P, Chapman KR, Cowie R, FitzGerald JM, Marciniuk DD, Maltais F, Buist AS, Road J, Hogg JC, Kirby M, Coxson H, Hague C, Leipsic J, O'Donnell DE, Aaron SD; CanCOLD Collaborative Research Group.

Thorax. 2015 Sep;70(9):822-9. doi: 10.1136/thoraxjnl-2015-206938. Epub 2015 Jun 5.

PMID:
26048404
39.

Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial.

Chapman KR, Burdon JG, Piitulainen E, Sandhaus RA, Seersholm N, Stocks JM, Stoel BC, Huang L, Yao Z, Edelman JM, McElvaney NG; RAPID Trial Study Group.

Lancet. 2015 Jul 25;386(9991):360-8. doi: 10.1016/S0140-6736(15)60860-1. Epub 2015 May 27.

PMID:
26026936
40.

Impact of pulmonary nontuberculous mycobacterial treatment on pulmonary function tests in patients with and without established obstructive lung disease.

Mehta M, Chapman KR, Heffer M, Marras TK.

Respirology. 2015 Aug;20(6):987-93. doi: 10.1111/resp.12565. Epub 2015 May 25.

41.

Alpha-1 antitrypsin deficiency in Canada: regional disparities in diagnosis and management.

Bradi AC, Audisho N, Casey DK, Chapman KR.

COPD. 2015 May;12 Suppl 1:15-21. doi: 10.3109/15412555.2015.1021908.

PMID:
25938286
42.

The prevalence of asthma and atopy in schoolchildren from Porto Alegre, Brazil, has plateaued.

Schuh C, Fritscher LG, Chapman KR, Fritscher CC.

Respir Med. 2015 Mar;109(3):308-11. doi: 10.1016/j.rmed.2015.01.014. Epub 2015 Jan 31.

43.

QVA149 Improves Lung Function, Dyspnea, and Health Status Independent of Previously Prescribed Medications and COPD Severity: A Subgroup Analysis from the SHINE and ILLUMINATE Studies.

Chapman KR, Bateman ED, Chen H, Hu H, Fogel R, Banerji D.

Chronic Obstr Pulm Dis. 2015 Jan 1;2(1):48-60. doi: 10.15326/jcopdf.2.1.2014.0140.

44.

Exacerbations in non-COPD patients: truth or myth--authors' response.

Tan WC, Bourbeau J, Aaron S, FitzGerald JM, Hernandez P, Cowie R, Chapman KR, Marciniuk D, Maltais F, Buist S, O'Donnell D, Sin DD; CanCOLD Collaborative Research Group.

Thorax. 2014 Nov;69(11):1050-1. doi: 10.1136/thoraxjnl-2014-205889. Epub 2014 Jul 4. No abstract available.

PMID:
24996635
45.

Exacerbation-like respiratory symptoms in individuals without chronic obstructive pulmonary disease: results from a population-based study.

Tan WC, Bourbeau J, Hernandez P, Chapman KR, Cowie R, FitzGerald JM, Marciniuk DD, Maltais F, Buist AS, O'Donnell DE, Sin DD, Aaron SD; CanCOLD Collaborative Research Group.

Thorax. 2014 Aug;69(8):709-17. doi: 10.1136/thoraxjnl-2013-205048. Epub 2014 Apr 4.

46.

Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study.

Decramer ML, Chapman KR, Dahl R, Frith P, Devouassoux G, Fritscher C, Cameron R, Shoaib M, Lawrence D, Young D, McBryan D; INVIGORATE investigators.

Lancet Respir Med. 2013 Sep;1(7):524-33. doi: 10.1016/S2213-2600(13)70158-9. Epub 2013 Aug 21.

PMID:
24461613
47.

A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study.

Chapman KR, Beeh KM, Beier J, Bateman ED, D'Urzo A, Nutbrown R, Henley M, Chen H, Overend T, D'Andrea P.

BMC Pulm Med. 2014 Jan 17;14:4. doi: 10.1186/1471-2466-14-4.

48.

Minimal clinically important differences in pharmacological trials.

Jones PW, Beeh KM, Chapman KR, Decramer M, Mahler DA, Wedzicha JA.

Am J Respir Crit Care Med. 2014 Feb 1;189(3):250-5. doi: 10.1164/rccm.201310-1863PP. Review.

PMID:
24383418
49.

Types, frequency and impact of asthma triggers on patients' lives: a quantitative study in five European countries.

Price D, Dale P, Elder E, Chapman KR.

J Asthma. 2014 Mar;51(2):127-35. doi: 10.3109/02770903.2013.846369. Epub 2013 Nov 4.

50.

Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN study.

Dahl R, Chapman KR, Rudolf M, Mehta R, Kho P, Alagappan VK, Chen H, Banerji D.

Respir Med. 2013 Oct;107(10):1558-67. doi: 10.1016/j.rmed.2013.05.016. Epub 2013 Jul 16.

Supplemental Content

Loading ...
Support Center